Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years.
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2014
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi; sanofi pasteur
- 08 Jul 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 07 Jan 2011 Results published in Vaccine.
- 16 Dec 2009 Immunogenicity results after single vaccination published in the Lancet.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History